Twice the output, half the runtime, and half the footprint of the UG 100® with greater flexibility and improved genomic ...

The key opportunities in the Global Personalized Medicine Biomarkers Market include advancements in genomic sequencing, growing reliance on targeted therapies, rising cancer and chronic disease ...

Generation Sequencing (NGS) market is set to surge from $14.79 billion in 2025 to $56.25 billion by 2033, with a robust CAGR of 18.17%. Key drivers include advancements in sequencing technologies, ...

Genomic sequencing has come a long way in a short time, and its potential to drive even faster innovations in precision medicine is enormous. To capitalize on that opportunity, however, health systems ...

Ultima Genomics, Hamilton partner to enable improved lab operations to drive sequencing at scale: Fremont, California Saturday, February 28, 2026, 11:00 Hrs [IST] Ultima Genomics, ...

Delays in time to first lenalidomide prescription fill for multiple myeloma. Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health ...

Located on the Buffalo Niagara Medical Campus and the first next-generation sequencing service provider in the region, UB's Genomics and Bioinformatics Core Facility provides high-quality services ...

Patients with multiple CALMs w/wo skinfold freckling and no other typical NF1 associated features (Lisch nodules, bone abnormalities, neurofibromas, optic pathway gliomas). The DNA-based ...

Patients with classic NF1 including the presence of cutaneous neurofibromas or Lisch nodules, as no genetic heterogeneity demonstrated so far associated with this phenotype. The NF1-only by NGS ...